The goal of this funding opportunity from JDRF is to accelerate the identification and validation of reagents that promote immune rebalance and the protection of beta cell function through modulating the trafficking of immune cells to the pancreatic islets.
Proposals submitted for this opportunity should describe the preclinical or clinical development of therapeutic strategies targeting the trafficking of disease-relevant immune cell populations. This program will award grants of up to $900k over 3 years.
The deadline for letters of intent is 17 January 2024. Notification of the full application request will be sent on 31 January 2024. The full application deadline (on invite only) is 28 February 2024. The response will be provided to applicants by 31 August 2024, with an earliest start date of 1 October 2024.